Found 16 clinical trials
A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib
This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a change (mutation) in the gene EGFR. Osimertinib alone is the usual treatment for metastatic EGFR-mutant lung cancer. Researchers think adding chemotherapy to …
- 37 views
- 23 Oct, 2022
- 12 locations
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (MP-PDAC-01)
uncontrolled CNS metastases (patients who require steroids should be on a stable or decreasing dose for at least 2 weeks) Subjects who have any contraindications for 5-FU, leucovorin, or oxaliplatin
- 1 views
- 29 Jun, 2022
- 1 location
A Brain Metastases Research Platform to Tackle the Challenge of CNS Metastases in Solid Tumours (BrainStorm)
Despite some encouraging data, systemic treatment of CNS metastases from solid tumors remains experimental. Better knowledge on the evolving epidemiology and biology of BM are key
- 30 views
- 05 Jul, 2022
- 16 locations
Diffusion-weighted MRI to Predict Treatment Response in Stereotactic Radiotherapy of Central Nervous System (CNS) Metastases
Stereotactic radiation therapy is an important and common method of treating brain metastases in patients with malignant disease. Today, however, there are no methods available to determine the metastasis' radiation sensitivity in advance and treatment responses can only be seen by changing of the size of the metastasis on conventional …
- 0 views
- 27 Jan, 2021
- 1 location
A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
This research study is studying a drug as a possible treatment for ALK-positive or ROS1-positive non-small cell lung cancer (NSCLC). The following drug will be involved in this study : Lorlatinib
- 0 views
- 25 Feb, 2022
- 1 location
Phase 1 Study of E6201 Plus Dabrafenib for the Treatment of Central Nervous System (CNS) Metastases From BRAF V600-Mutated Metastatic Melanoma
This phase I tests the safety, side effects, and best dose of E6201 in combination with dabrafenib in treating patients with BRAF V600 mutated melanoma that has spread to the central nervous system (central nervous system metastases). E6201 may stop the growth of tumor cells by blocking some of the …
- 0 views
- 23 Oct, 2022
- 1 location
Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer
the early onset of CNS metastases (such as brain cancer). If the researchers can identify the early onset of CNS metastases, they can immediately treat that cancer and possibly prevent it from
- 0 views
- 04 Oct, 2022
- 1 location
131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases
Children with a neuroblastoma diagnose and central nervous system (CNS)/leptomeningeal metastases will be given up to 2 rounds of intracerebroventricular treatment with a radiolabelled monoclonal antibody, 131I-omburtamab to evaluate efficacy and safety
- 82 views
- 16 Feb, 2022
- 1 location
Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
localized intraocular phase. The advanced retinoblastoma cases with central nervous system metastasis (CNS)is associated with exceedingly poor prognosis. CNS metastasis is the main cause of death in
- 0 views
- 09 Sep, 2021
- 1 location
Furmonertinib in First-line Treatment of Patients With CNS Metastatic EGFR Mutation Positive NSCLC
EGFR mutation positive advanced NSCLC patients with CNS metastases have poor prognosis, second-line furmonertinib dose at 160mg level in EGRF T790M mutation positive CNS metastatic NSCLC have
- 0 views
- 02 Jun, 2022
- 1 location
- 1
- 2